Severe Immune-Related Adverse Events Associated with Durable Antitumor Responses Following Immune Checkpoint Inhibitor Therapy: Two Case Reports
Background Immune checkpoint inhibitors (ICIs) have achieved remarkable success in treating advanced cancers, yet the accompanying immune-related adverse events (irAEs) pose a major challenge to their clinical application. Growing evidence suggests an association between irAEs and improved clinical outcomes; however, t...